Document 0367
 DOCN  M9440367
 TI    Hepatitis B vaccination in prisons: the Catalonian experience.
 DT    9404
 AU    Bayas JM; Bruguera M; Martin V; Vidal J; Rodes J; Salleras LY; Servicio
       de Medicina Preventiva, Hospital Clinic i Provincial,; Barcelona, Spain.
 SO    Vaccine. 1993 Nov;11(14):1441-4. Unique Identifier : AIDSLINE
       MED/94144255
 AB    A pilot programme of hepatitis B vaccination was set up in three prisons
       to assess the feasibility and results of this method of reaching a
       high-risk population. Hepatitis B vaccine was offered to all inmates who
       lacked serological markers for hepatitis B virus. The antibody response
       was assessed in those who received two or three doses of vaccine.
       Candidates for vaccination were 41% of 1755 imprisoned men (20% of
       intravenous drug users (IVDU) and 63% of non-IVDU), but complete
       vaccination could be given to only 33% of candidates. A further 29%
       received two doses. Seroconversion to anti-HBs (titres > 10 IU l-1)
       occurred in 33% of vaccinees after two doses and in 76% after three
       doses. The overall rate of susceptible inmates who became protected for
       hepatitis B was 34%. The seroconversion rate was higher when the
       interval between the first two doses was shorter than 3 weeks (91%),
       than in cases with an interval of 3-6 weeks (79%) or longer than 6 weeks
       (33%). Age greater than 35 years and history of IVDU were associated
       with a lower response to the vaccine, while anti-HIV seropositivity did
       not influence the response. In conclusion, vaccination of prisoners
       susceptible to HBV may achieve protection in at least a third of cases.
       Shortening intervals between the priming doses of vaccine may improve
       compliance and increases the response.
 DE    Adolescence  Adult  Antibody Formation  Feasibility Studies  Hepatitis
       B/BLOOD/EPIDEMIOLOGY/PREVENTION & CONTROL  Hepatitis B Antibodies/BLOOD
       Hepatitis B Vaccines/ADMINISTRATION & DOSAGE/IMMUNOLOGY/  *THERAPEUTIC
       USE  Human  HIV Infections/BLOOD/IMMUNOLOGY  Male  Pilot Projects
       Prisons  Seroepidemiologic Methods  Spain  *Vaccination  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).